LEWISVILLE, Texas / Oct 21, 2024 / Business Wire / Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that the Company will participate in the Stifel 2024 Healthcare Conference in New York. Management is scheduled to present on Monday, November 18, 2024 at 8:35 am ET.
Interested parties can access the live and archived webcast of the presentation in the “Events & Presentations” section of the Orthofix investor relations website at ir.orthofix.com.
Internet Posting of Information
Orthofix routinely posts information that may be important to investors in the “Investors” section of its website at www.orthofix.com. The Company encourages investors and potential investors to consult the Orthofix website regularly for important information about Orthofix.
About Orthofix
Orthofix is a global medical technology company headquartered in Lewisville, Texas. By providing medical technologies that heal musculoskeletal pathologies, we deliver exceptional experiences and life-changing solutions to patients around the world. Orthofix offers a comprehensive portfolio of spinal hardware, bone growth therapies, specialized orthopedic solutions, biologics and enabling technologies, including the 7D FLASH™ navigation system. To learn more, visit Orthofix.com and follow on LinkedIn.
| Last Trade: | US$13.48 |
| Daily Change: | -0.19 -1.39 |
| Daily Volume: | 172,072 |
| Market Cap: | US$515.070M |
March 19, 2025 February 25, 2025 November 07, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
